Novartis and TARGET PharmaSolutions have entered a long-term strategic alliance for TARGET-NASH
TARGET PharmaSolutions enroll first patient in IBD Community
TARGET PharmaSolutions has just announced the enrollment of the first participant in its Inflammatory Bowel Disease (IBD) community. This community will include adult and pediatric patients with ulcerative colitis, Crohn's disease, and indeterminate colitis. This is the first step in moving towards creating a bio-repository stakeholders can access for translational studies.